Capture.JPG (49.8 kB)
Teprotumumab: First Approval
online resource
posted on 2020-03-10, 20:18 authored by Anthony MarkhamCompliance with Ethical Standards
Funding The preparation of this review was not supported by any external funding.
Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Anthony Markham is a contracted employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found here
Abstract
Teprotumumab (teprotumumab-trbw; TEPEZZATM – Horizon Therapeutics) is a monoclonal antibody insulin-like growth factor-I receptor (IGF-IR) antagonist developed for the treatment of thyroid eye disease (Graves ophthalmopathy/orbitopathy, thyroid-associated opthamology). Based on positive results from two multinational clinical trials teprotumumab was recently approved for this indication in the US. This article summarizes the milestones in the development of teprotumumab leading to this first approval for thyroid eye disease.
© Springer Nature Switzerland AG 2020
